GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » E10

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) E10 : $-906.28 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cyclacel Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-6.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-906.28 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 32.70% per year. During the past 5 years, the average E10 Growth Rate was 32.40% per year. During the past 10 years, the average E10 Growth Rate was 31.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cyclacel Pharmaceuticals was 38.30% per year. The lowest was 20.40% per year. And the median was 30.00% per year.

As of today (2024-04-30), Cyclacel Pharmaceuticals's current stock price is $1.36. Cyclacel Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-906.28. Cyclacel Pharmaceuticals's Shiller PE Ratio of today is .


Cyclacel Pharmaceuticals E10 Historical Data

The historical data trend for Cyclacel Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals E10 Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,477.05 -2,978.61 -2,202.23 -1,603.30 -906.28

Cyclacel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,603.30 -1,080.39 -1,139.80 -999.10 -906.28

Competitive Comparison of Cyclacel Pharmaceuticals's E10

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Shiller PE Ratio falls into.



Cyclacel Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cyclacel Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-6.23/129.4194*129.4194
=-6.230

Current CPI (Dec. 2023) = 129.4194.

Cyclacel Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -900.004 99.695 -1,168.349
201406 -792.003 100.560 -1,019.303
201409 -792.003 100.428 -1,020.639
201412 -756.003 99.070 -987.602
201503 -684.003 99.621 -888.599
201506 -357.000 100.684 -458.889
201509 -285.000 100.392 -367.407
201512 -360.001 99.792 -466.880
201603 -312.000 100.470 -401.898
201606 -303.000 101.688 -385.631
201609 -258.000 101.861 -327.802
201612 -207.000 101.863 -262.999
201703 -114.000 102.862 -143.433
201706 -150.000 103.349 -187.838
201709 -273.000 104.136 -339.284
201712 -52.137 104.011 -64.873
201803 -36.000 105.290 -44.250
201806 -48.000 106.317 -58.430
201809 -54.000 106.507 -65.617
201812 -51.000 105.998 -62.269
201903 -41.550 107.251 -50.138
201906 -31.950 108.070 -38.262
201909 -34.050 108.329 -40.679
201912 -42.000 108.420 -50.135
202003 -22.200 108.902 -26.383
202006 -8.700 108.767 -10.352
202009 -7.050 109.815 -8.309
202012 -20.100 109.897 -23.671
202103 -7.500 111.754 -8.686
202106 -8.400 114.631 -9.484
202109 -8.100 115.734 -9.058
202112 -8.100 117.630 -8.912
202203 -6.300 121.301 -6.722
202206 -6.900 125.017 -7.143
202209 -6.450 125.227 -6.666
202212 -9.000 125.222 -9.302
202303 -7.050 127.348 -7.165
202306 -6.600 128.729 -6.635
202309 -7.200 129.860 -7.176
202312 -6.230 129.419 -6.230

Add all the adjusted EPS together and divide 10 will get our e10.


Cyclacel Pharmaceuticals  (NAS:CYCC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cyclacel Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Executives
Spiro Rombotis director, officer: President & C.E.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron director, officer: E.V.P., Finance & C.O.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson director 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker director 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker director C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum officer: Chief Medical Officer 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd. 10 percent owner 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart 10 percent owner P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems director C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017